Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 101–200 of 1,000
ATRX and DAXX: Mechanisms and Mutations
Dyer, M. A., Qadeer, Z. A., Valle-Garcia, D., & Bernstein, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026567 · Cited by 194
“ATRX/DAXX LOSS AND ALT The ALT pathway in cancer was first described in 1997 (Bryan et al. 1997).”
BackgroundTelomeric Strategies: Means to an End
Jain, D., & Cooper, J. P. (2010) · Annual Review of Genetics · doi:10.1146/annurev-genet-102108-134841 · Cited by 196
“However, 10% to 15% of cancer cells maintain telomeres by an alternative strategy termed alternative lengthening of telomeres (ALT) (25).”
BackgroundStavropoulos, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.25.3135 · Cited by 197
Role of Telomerase in Normal and Cancer Cells
Meyerson, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2626 · Cited by 204
Molecular mechanisms of activity and derepression of alternative lengthening of telomeres
Pickett, H. A., & Reddel, R. R. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3106 · Cited by 203
Self-citationMin, J., Wright, W. E., & Shay, J. W. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00226-17 · Cited by 195
“However, 15% of cancer cells activate an alternative lengthening of telomeres (ALT) pathway, which is a telomerase-independent telomere maintenance mechanism (4).”
BackgroundTelomerase RNA Accumulates in Cajal Bodies in Human Cancer Cells
Zhu, Y., Tomlinson, R. L., Lukowiak, A. A., Terns, R. M., & Terns, M. P. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-07-0525 · Cited by 193
“Furthermore, signals were not observed in VA13 cells, an unusual ALT cell line that lacks hTR transcripts (as well as hTERT; Bryan et al., 1997b; Guiducci et al., 2001; Figure 1C).”
BackgroundDantzer, F., Giraud-Panis, M.-J., Jaco, I., Amé, J.-C., Schultz, I., Blasco, M., Koering, C.-E., Gilson, E., Ménissier-de Murcia, J., de Murcia, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.4.1595-1607.2004 · Cited by 186
“tive lengthening of telomeres (ALT) pathway (11, 21, 28, 42).”
BackgroundAlternative lengthening of telomeres, telomerase, and cancer
Reddel, R. R. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00702-4 · Cited by 191
Self-citationGomes, N. M. V., Shay, J. W., & Wright, W. E. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.07.031 · Cited by 190
“The ALT pathway is characterized by an array of phenotypes such as a very heterogeneous distribution of telomere sizes and length fluctuations, ALT-associated PML bodies (APBs), higher levels of telomere sister chromatic exchanges (T-SCE), and raised levels of C-circles [17].”
BackgroundInfluentialGorlick, R. G., Anderson, P. M., Andrulis, I. L., Arndt, C., Beardsley, G. P., Bernstein, M. L., Bridge, J. A., Cheung, N. V., Dome, J. S., Ebb, D. H., et al. (2003) · PubMed · Cited by 208
Li, S., Rosenberg, J. E., Donjacour, A. A., Botchkina, I. L., Hom, Y. K., Cunha, G. R., & Blackburn, E. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0953 · Cited by 194
“This telomerase-negative cell line maintains its telomeres by a telomerase-independent mechanism, alternate lengthening of telomeres (ALT), and expresses neither hTert nor hTER ( 42 ).”
BackgroundTrisubstituted Acridine Derivatives as Potent and Selective Telomerase Inhibitors
Harrison, R. J., Cuesta, J., Chessari, G., Read, M. A., Basra, S. K., Reszka, A. P., Morrell, J., Gowan, S. M., Incles, C. M., Tanious, F. A., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0308693 · Cited by 186
G-Quadruplexes at Telomeres: Friend or Foe?
Bryan, T. M. (2020) · Molecules · doi:10.3390/molecules25163686 · Cited by 187
Self-citationOpresko, P. L. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg034 · Cited by 187
Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks
Zhang, J.-M., & Zou, L. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00391-6 · Cited by 181
Damle, R. N., Batliwalla, F. M., Ghiotto, F., Valetto, A., Albesiano, E., Sison, C., Allen, S. L., Kolitz, J., Vinciguerra, V. P., Kudalkar, P., et al. (2004) · Blood · doi:10.1182/blood-2003-04-1345 · Cited by 182
POT1 and TRF2 Cooperate To Maintain Telomeric Integrity
Yang, Q., Zheng, Y.-L., & Harris, C. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.3.1070-1080.2005 · Cited by 182
“Maintenance of the telomeric TTAGGG repeats at human chromosome ends, either by telomerase (13) or by an alternative mechanism (9), is essential for immortalized cells in vitro to escape from the normal limitations of the proliferation capacity.”
BackgroundTime to Talk SENS: Critiquing the Immutability of Human Aging
DE GREY, A. D. N. J., AMES, B. N., ANDERSEN, J. K., BARTKE, A., CAMPISI, J., HEWARD, C. B., McCARTER, R. J. M., & STOCK, G. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02115.x · Cited by 186
Methylation of the human telomerase gene CpG island.
Dessain, S. K., Yu, H., Reddel, R. R., Beijersbergen, R. L., & Weinberg, R. A. (2000) · PubMed · Cited by 231
Self-citationChang, S., Khoo, C. M., Naylor, M. L., Maser, R. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1029903 · Cited by 183
“Moreover, ∼80% to 90% of human tumors possess telomerase activity, whereas the remainder maintains telomeres via a recombination-mediated process termed ALT (for alternative lengthening of telomeres; Kim et al. 1994; Bryan et al. 1997; Shay and Bacchetti 1997).”
BackgroundDe Vitis, M., Berardinelli, F., & Sgura, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020606 · Cited by 182
“Very recently, it was demonstrated that highly aggressive metastatic melanoma cells were not able to maintain telomeres, as was already suggested by previous studies [94,117].”
BackgroundResultUlaner, G. A., Huang, H.-Y., Otero, J. E., Zhao, Z., Ben‐Porat, L., Satagopan, J. M., Gorlick, R. G., Meyers, P. A., Healey, J. H., Huvos, A. G., et al. (2003) · PubMed · Cited by 210
Telomere maintenance without telomerase
Lundblad, V. (2002) · Oncogene · doi:10.1038/sj.onc.1205079 · Cited by 182
“In fact, although most immortalized human cells, including tumor cells, have substantially upregulated telomerase (Shay and Bacchetti, 1997), a subset of immortalized cells do not display high levels of telomerase activity (Bryan et al., 1995, 1997).”
BackgroundAlternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas
Scheel, C., Schaefer, K.-L., Jauch, A., Keller, M., Wai, D., Brinkschmidt, C., van Valen, F., Boecker, W., Dockhorn-Dworniczak, B., & Poremba, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204493 · Cited by 182
“Stem cells (Harle and Boukamp, 1996), stimulated lymphocytes (Broccoli et al., 1995; Hiyama et al., 1995; Counter et al., 1995) and di erent highly proliferative tissues (Hiyama et al., 1996; Takubo et al., 1997; Bryan et al., 1997) exhibit TA.”
BackgroundMin, J., Wright, W. E., & Shay, J. W. (2019) · Genes & Development · doi:10.1101/gad.324905.119 · Cited by 173
“However, cancers ofmesenchymal origin, such as sarcomas and soft tissue tumors, frequently acquire a telomerase-independent TMM, which has been termed alternative lengthening of telomeres (ALT) (Bryan et al. 1997).”
BackgroundToward specific functions of poly(ADP-ribose) polymerase-2
Yélamos, J., Schreiber, V., & Dantzer, F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.003 · Cited by 165
Telomere maintenance mechanisms and cellular immortalization
Colgin, L. M., & Reddel, R. R. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80014-8 · Cited by 176
Self-citationNg, L. J., Cropley, J. E., Pickett, H. A., Reddel, R. R., & Suter, C. M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn1030 · Cited by 158
“About 10–15% of tumours exhibit telomere stabilization in the absence of telomerase activity, via the alternative lengthening of telomeres (ALT) mechanism (7).”
BackgroundSelf-citationStop pulling my strings — what telomeres taught us about the DNA damage response
Lazzerini-Denchi, E., & Sfeir, A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.43 · Cited by 170
Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells
Conomos, D., Stutz, M. D., Hills, M., Neumann, A. A., Bryan, T. M., Reddel, R. R., & Pickett, H. A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201207189 · Cited by 165
“ALT cells display phenotypic characteristics suggestive of recombination-mediated telomere replication, including telomere length heterogeneity (Bryan et al., 1995, 1997; Perrem et al., 2001), an abundance of extrachromosomal circular and linear telomeric DNA (Tokutake et al., 1998; Cesare and…”
BackgroundSelf-citationTelomere maintenance by telomerase and by recombination can coexist in human cells
Cerone, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1945 · Cited by 172
“Activation of ALT in tumor cells is a much rarer event than activation of telomerase (20), and may normally occur under selective pressure when expression of the enzyme is prevented (38,39).”
Backgroundp53 and disease: when the guardian angel fails
Royds, J. A., & Iacopetta, B. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401913 · Cited by 168
Human Telomerase Inhibition by Regioisomeric Disubstituted Amidoanthracene-9,10-diones
Perry, P. J., Reszka, A. P., Wood, A. A., Read, M. A., Gowan, S. M., Dosanjh, H. S., Trent, J. O., Jenkins, T. C., Kelland, L. R., & Neidle, S. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm981067o · Cited by 165
Grobelny, J. V., Godwin, A. K., & Broccoli, D. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.24.4577 · Cited by 165
Chromosome rearrangements resulting from telomere dysfunction and their role in cancer
Murnane, J. P., & Sabatier, L. (2004) · BioEssays · doi:10.1002/bies.20125 · Cited by 179
“Most tumors demonstrate telomerase activity,((15,16)) although tumors maintaining telomeres through the ALT mechanism have also been observed.((17))”
Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway
Chen, Y.-A., Shen, Y.-L., Hsia, H.-Y., Tiang, Y.-P., Sung, T.-L., & Chen, L.-Y. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3498 · Cited by 160
Association and regulation of the BLM helicase by the telomere proteins TRF1 and TRF2
Lillard-Wetherell, K., Machwe, A., Langland, G. T., Combs, K. A., Behbehani, G. K., Schonberg, S. A., German, J., Turchi, J. J., Orren, D. K., & Groden, J. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh193 · Cited by 157
Jiang, W.-Q., Zhong, Z.-H., Henson, J. D., Neumann, A. A., Chang, A. C.-M., & Reddel, R. R. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.7.2708-2721.2005 · Cited by 155
“(American Type Culture Collection), both of which are ALT (3, 4) were”
BackgroundSelf-citationLi, S., Crothers, J., Haqq, C. M., & Blackburn, E. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502782200 · Cited by 158
The Role of Telomere Biology in Cancer
Xu, L., Li, S., & Stohr, B. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164030 · Cited by 160
Transformation of normal human cells in the absence of telomerase activation
Seger, Y. R., Garcı́a-Cao, M., Piccinin, S., Cunsolo, C. L., Doglioni, C., Blasco, M. A., Hannon, G. J., & Maestro, R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00183-6 · Cited by 159
“Examinatenance (ALT) (Dunham et al., 2000; Bryan and Reddel, 1997; tion of cells that are explanted into culture following tumor forHoare et al., 2001; Bryan et al., 1997).”
Bachschmid, M. M., Schildknecht, S., Matsui, R., Zee, R., Haeussler, D., A. Cohen, R., Pimental, D., & Loo, B. V. D. (2013) · Annals of Medicine · doi:10.3109/07853890.2011.645498 · Cited by 152
1,4- and 2,6-Disubstituted Amidoanthracene-9,10-dione Derivatives as Inhibitors of Human Telomerase
Perry, P. J., Gowan, S. M., Reszka, A. P., Polucci, P., Jenkins, T. C., Kèlland, L. R., & Neidle, S. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9801105 · Cited by 171
Telomere maintenance and cancer ? look, no telomerase
Neumann, A. A., & Reddel, R. R. (2002) · Nature reviews. Cancer · doi:10.1038/nrc929 · Cited by 191
“The presence of ALT in human cancer samples showed most clearly that it is not an artefact of cell cultur”
BackgroundSelf-citationSevere growth defect in mouse cells lacking the telomerase RNA component
Niida, H., Matsumoto, T., Satoh, H., Shiwa, M., Tokutake, Y., Furuichi, Y., & Shinkai, Y. (1998) · Nature Genetics · doi:10.1038/580 · Cited by 156
“The telomerase-independent telomere maintenance is also observed in some in vitro immortalized cell lines, tumour-derived cell lines and primary tumour”
BackgroundTelomere structure and telomerase in health and disease
GOMEZ, D. E., ARMANDO, R. G., FARINA, H. G., MENNA, P. L., CERRUDO, C. S., GHIRINGHELLI, P. D., & ALONSO, D. F. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1611 · Cited by 145
“means, this has been called ALT (alternative lengthening of telomeres) (56).”
BackgroundRecombination-mediated lengthening of terminal telomeric repeats requires the Sgs1 DNA helicase
Cohen, H., & Sinclair, D. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061579598 · Cited by 156
Transcriptional Regulation of Telomerase Reverse Transcriptase (TERT) by MYC
Khattar, E., & Tergaonkar, V. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00001 · Cited by 158
“Telomere length is maintained by telomerase in 90% of human cancers, while 10% of cancers utilize an alternative mechanism of telomere lengthening termed ALT (Kim et al., 1994; Bryan et al., 1995, 1997; Shay and Bacchetti, 1997).”
BackgroundPossible association between gastric cancer and bracken fern in Venezuela: An epidemiologic study
Alonso‐Amelot, M. E., & Avendaño, M. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010115)91:2 · Cited by 66
Vascular cell senescence and vascular aging
Minamino, T., Miyauchi, H., Yoshida, T., Tateno, K., Kunieda, T., & Komuro, I. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2003.11.010 · Cited by 164
“[39] Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR.”
BackgroundWang, L., Dittmer, D. P., Tomlinson, C. C., Fakhari, F. D., & Damania, B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3680 · Cited by 163
“These results suggest that telomere maintenance in primary HUVECs expressing K1 is probably carried out by an ALT mechanism (33, 34).”
BackgroundMice with bad ends: mouse models for the study of telomeres and telomerase in cancer and aging
Blasco, M. A. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600598 · Cited by 166
“ALT-positive cells are characterized by the simultaneous presence of long and short telomeres in the same nucleus, as well as by the co-localization of telomerebinding proteins and PML in the so-called ALT-associated PML bodies (APB) (Bryan et al, 1997; Dunham et al, 2000).”
BackgroundFANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres
Pan, X., Drosopoulos, W. C., Sethi, L., Madireddy, A., Schildkraut, C. L., & Zhang, D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708065114 · Cited by 164
Telomeres, interstitial telomeric repeat sequences, and chromosomal aberrations
Bolzán, A. D., & de Bianchi, M. S. A. (2006) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2005.12.003 · Cited by 166
García-Expósito, L., Bournique, E., Bergoglio, V., Bose, A., González, J. B., Zhang, S., Roncaioli, J. L., Lee, M., Wallace, C. T., Watkins, S. C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.048 · Cited by 158
“However, telomerase is suppressed in a significant number of cancers that maintain telomere length by engaging the alternative lengthening of telomeres (ALT) mechanism (Bryan et al., 1997).”
Is telomerase a viable target in cancer?
Buseman, C. M., Wright, W. E., & Shay, J. W. (2012) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.07.006 · Cited by 148
“The approximately 10% of cancer cells that do not upregulate telomerase have been found either to be “mortal” tumor cells or to maintain their telomeres through a telomere recombination pathway called ALT (alternative lengthening of telomeres) [52].”
The chromatin remodelling factor ATRX suppresses R‐loops in transcribed telomeric repeats
Nguyen, D. T. T., Voon, H. P. J., Xella, B., Scott, C., Clynes, D., Babbs, C., Ayyub, H., Kerry, J., Sharpe, J. A., Sloane‐Stanley, J., et al. (2017) · EMBO Reports · doi:10.15252/embr.201643078 · Cited by 149
“In the 15% of cancers that use this pathway, the banks of telomeric repeats are maintained by homology-directed repair (HDR) rather than by increasing the expression of telomerase [20,21].”
Telomeres, telomerase, and myc. An update
Cerni, C. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(99)00091-5 · Cited by 160
(2003) · PubMed · Cited by 146
Telomerase activation, cellular immortalization and cancer
Hahn, W. C., & Meyerson, M. (2001) · Annals of Medicine · doi:10.3109/07853890109002067 · Cited by 142
Gavia-García, G., Rosado-Pérez, J., Arista-Ugalde, T. L., Aguíñiga-Sánchez, I., Santiago‐Osorio, E., & Mendoza-Núñez, V. M. (2021) · Biology · doi:10.3390/biology10040253 · Cited by 167
“In addition, 5–10% of the tumors use a molecular mechanism denominated the alternative lengthening of telomeres (ALT) that provides the capacity of maintaining the telomere length even without telomerase [54,55].”
BackgroundInhibition of human telomerase by 2′- O -methyl-RNA
Pitts, A. E., & Corey, D. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11549 · Cited by 144
Epigenetic silencing of multiple interferon pathway genes after cellular immortalization
Kulaeva, O. I., Drăghici, S., Tang, L., Kraniak, J. M., Land, S. J., & Tainsky, M. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206594 · Cited by 154
“Certain immortalized human cell lines (Bryan et al., 1995) and some tumors (Bryan et al., 1997) maintain their telomeres in the absence of detectable telomerase activity by a mechanism, referred to as alternative lengthening of telomeres (ALT), that may involve telomere–telomere recombination…”
BackgroundTelomere Maintenance Mechanisms in Cancer
Gaspar, T. B., Sá, A., Lopes, J. M., Sobrinho-Simões, M. A., Soares, P., & Vinagre, J. (2018) · Genes · doi:10.3390/genes9050241 · Cited by 156
“Glioblastoma [303,457,458], osteosarcoma [328,459], metastases of cutaneous melanoma [460,461], and other tumour types [35,45] presented such a phenotype.”
BackgroundInfluentialCosta, A., Daidone, M. G., Daprai, L., Villa, R., Cantù, S., Pilotti, S., Mariani, L., Gronchi, A., Henson, J. D., Reddel, R. R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0273 · Cited by 140
“Coexistence of two TMMs in the same tumor, previously shown in other human tumor types ( 4 , 9), occurred occasionally in our study and in the liposarcomas analyzed by Johnson et al. (14).”
ResultSelf-citationCancer and Telomeres—An ALTernative to Telomerase
Shay, J. W., Reddel, R. R., & Wright, W. E. (2012) · Science · doi:10.1126/science.1222394 · Cited by 153
Self-citationPersistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence
Datta, A., Bellon, M., Sinha-Datta, U., Bazarbachi, A., Lepelletier, Y., Canioni, D., Waldmann, T. A., Hermine, O., & Nicot, C. (2006) · Blood · doi:10.1182/blood-2006-01-0067 · Cited by 139
T cells and aging update February 1999
Pawelec, G. (1999) · Frontiers in Bioscience · doi:10.2741/a424 · Cited by 139
“More recent data have confirmed and taken this idea further (308).”
Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells
Varley, H., Pickett, H. A., Foxon, J. L., Reddel, R. R., & Royle, N. J. (2002) · Nature Genetics · doi:10.1038/ng834 · Cited by 153
“Some telomerase-negative tumors and immortal cell lines maintain long heterogeneous telomeres by the ALT (alternative lengthening of telomeres) mechanis”
BackgroundSelf-citationAlternative lengthening of telomeres in normal mammalian somatic cells
Neumann, A. A., Watson, C. M., Noble, J. R., Pickett, H. A., Tam, P. P. L., & Reddel, R. R. (2013) · Genes & Development · doi:10.1101/gad.205062.112 · Cited by 137
“Some immortalized cell lines and cancers lengthen their telomeres without telomerase (Bryan et al. 1995, 1997) by synthesizing new telomeric DNA using telomeric DNA as the copy template (for review, see Cesare and Reddel 2010).”
MethodSelf-citationLeeansyah, E., Cameron, P. U., Solomon, A., Tennakoon, S., Velayudham, P., Gouillou, M., Spelman, T., Hearps, A., Fairley, C., Smit, D. V., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit006 · Cited by 136
“ening of telomeres has been described in multiple human cell types [40–42] and would be of interest to explore in future studies.”
BackgroundThe Nucleolar Localization Domain of the Catalytic Subunit of Human Telomerase
Etheridge, K. T., Banik, S. S. R., Armbruster, B. N., Zhu, Y., Terns, R. M., Terns, M. P., & Counter, C. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201227200 · Cited by 135
Hrdličková, R., Nehyba, J., & Bose, H. R. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00550-12 · Cited by 123
“Telomerase activity was undetectable in BJ, WI38, and U2OS cells, but the other two cell lines were telomerase positive (9, 10).”
BackgroundLi, F., Deng, Z., Zhang, L., Wu, C., Jin, Y., Hwang, I., Vladimirova, O. V., Xu, L., Yang, L., Lu, B., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201796659 · Cited by 142
“…telomerase that adds telomere repeats to the chromosomal ends (Kim et al , 1994), a remaining 10 – 15% of human cancers adopt a telomerase-independent mechanism, termed alternative lengthening of telomeres (ALT), to potentiate their replicative immortality (Bryan et al , 1997; Henson et al , 2005).”
Recombinational Telomere Elongation Promoted by DNA Circles
Natarajan, S., & McEachern, M. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4512-4521.2002 · Cited by 148
Graakjær, J., Bischoff, C., Korsholm, L., Holstebroe, S., Vach, W., Bohr, V. A., Christensen, K., & Kølvraa, S. (2003) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(03)00081-2 · Cited by 139
Loe, T. K., Li, J. S. Z., Zhang, Y., Azeroglu, B., Boddy, M. N., & Denchi, E. L. (2020) · Genes & Development · doi:10.1101/gad.333963.119 · Cited by 143
“However, approximately 10-15% of cancers, in particular those of mesenchymal origin, rely on a different mechanism for telomere extension, coined Alternative Lengthening of Telomeres (ALT) (Bryan et al. 1997; Dunham et al.).”
BackgroundTranscriptional activation of hTERT through the NF-κB pathway in HTLV-I–transformed cells
Sinha-Datta, U., Horikawa, I., Michishita, E., Datta, A., Sigler-Nicot, J. C., Brown, M., Kazanji, M., Barrett, J. C., & Nicot, C. (2004) · Blood · doi:10.1182/blood-2003-12-4251 · Cited by 126
Mechanisms of chromosome instability in cancers
Jefford, C. E., & Irminger‐Finger, I. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.02.005 · Cited by 159
Wu, G., Jiang, X., Lee, W., & Chen, P. (2003) · PubMed · Cited by 158
Role of telomeres and telomerase in genomic instability, senescence and cancer
Deng, Y., & Chang, S. S. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700673 · Cited by 154
Oncogene-induced Cellular Senescence
Chandeck, C., & Mooi, W. J. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181c66f4e · Cited by 116
“An ALT (alternative lengthening of telomeres) phenomenon similarly allows lengthening of telomeres, but in the absence of telomerase.(25) As would be expected, outgrowth of malignant tumors is possible only when replicative senescence is not effective.”
BackgroundPML interaction with p53 and its role in apoptosis and replicative senescence
Pearson, M. A., & Pelicci, P. G. (2001) · Oncogene · doi:10.1038/sj.onc.1204856 · Cited by 143
“…that rare clones that escape from crisis period have re-established the ability to maintain their telomere length, either due to reactivation of TERT, or through an Alternative Lengthening of Telomere (ALT), that is independent of telomerase (Lundblad and Blackburn, 1993; Bryan et al., 1995, 1997).”
BackgroundWang, L. L. (2005) · The Cancer Journal · doi:10.1097/00130404-200507000-00005 · Cited by 129
Marrone, A., Stevens, D., Vulliamy, T., Dokal, I., & Mason, P. J. (2004) · Blood · doi:10.1182/blood-2004-05-1829 · Cited by 126
SHQ1 is required prior to NAF1 for assembly of H/ACA small nucleolar and telomerase RNPs
Grozdanov, P. N., Roy, S., Kittur, N. D., & Meier, U. T. (2009) · RNA · doi:10.1261/rna.1532109 · Cited by 139
“Because telomerase RNA (hTR) was not detectable in U2OS cells, which maintain their telomeres through an alternative (ALT) pathway (Bryan et al. 1997), we included HeLa cells in all our analyses.”
BackgroundTseng, S.-F., Lin, J.-J., & Teng, S.-C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl786 · Cited by 120
Sizing the ends: Normal length of human telomeres
Samassékou, O., Gadji, M., Drouin, R., & Yan, J. (2010) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2010.07.005 · Cited by 143
“Alternative lengthening of telomeres Cancer and immortalized cells can utilize non-telomerase echanisms, called alternative lengthening of telomeres or ALT, o maintain telomere length (Bryan et al., 1995, 1997).”
BackgroundEvolving views of telomerase and cancer
Blasco, M. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00085-0 · Cited by 123
Telomere uncapping and alternative lengthening of telomeres
Cesare, A. J., & Reddel, R. R. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.11.006 · Cited by 143
Self-citationGenetic and epigenetic modulation of telomerase activity in development and disease
Liu, L., Lai, S. R., Andrews, L. G., & Tollefsbol, T. O. (2004) · Gene · doi:10.1016/j.gene.2004.06.011 · Cited by 137
Tong, W.-M., Hande, M. P., Lansdorp, P. M., & Wang, Z.-Q. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4046-4054.2001 · Cited by 121
“One explanation for this observation is that the absence of PARP eventually causes telomere elongation via alternative pathways (6), such as the recombination-mediated elongation in yeast (31).”
BackgroundRecombination: a means to an end in human cells
Smith, S. H. (2000) · Nature Genetics · doi:10.1038/82492 · Cited by 126
RAD50 function is essential for telomere maintenance in Arabidopsis
Gallego, M. E., & White, C. I. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1711 · Cited by 118
Telomere variability in the monocotyledonous plant order Asparagales
Sýkorová, E., Lim, K. Y., Kunická, Z., Chase, M. W., Bennett, M. D., Fajkus, J., & Leitch, A. R. (2003) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2003.2446 · Cited by 123
“Such alternative lengthening of telomere (ALT) mechanisms have also been shown to occur in rare cases of human telomerase-negative tumours and in vitro immortalized cell-lines (Bryan et al. 1997).”
BackgroundTelomereHunter – in silico estimation of telomere content and composition from cancer genomes
Feuerbach, L., Sieverling, L., Deeg, K. I., Ginsbach, P., Hutter, B., Buchhalter, I., Northcott, P. A., Mughal, S. S., Chudasama, P., Glimm, H., et al. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2851-0 · Cited by 123
Ragupathi, A., Singh, M., Perez, A. M., & Zhang, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1133472 · Cited by 133
“These cancers adopt the so-called Alternative Lengthening of Telomere (ALT) pathway to maintain their telomeres (Bryan et al., 1995; Bryan et al., 1997).”
BackgroundZhou, J.-M., Zhu, X.-F., Lu, Y.-J., Deng, R., Huang, Z.-S., Mei, Y.-P., Wang, Y., Huang, W.-L., Liu, Z.-C., Gu, L.-Q., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209067 · Cited by 126
“Telomerase is a ribonucleoprotein enzyme that maintains the protective structures at the ends of eukaryotic chromosomes, called telomeres (Bryan et al., 1997; Keith et al., 2001).”
BackgroundTelomere biology in human aging and aging syndromes
Klapper, W., Parwaresch, R., & Krupp, G. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00223-8 · Cited by 136
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.